ClinicalTrials.gg
TerminatedNCT00625872SGA-POWERUpdated Feb 29, 2012Results posted

Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy

A Phase 3 interventional study of Somatropin and Somatropin in Growth Hormone Therapy and Infant, Small for Gestational Age, sponsored by Pfizer. Terminated at 10 sites in Germany. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2012-02-29.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
The study terminated on 19-Jan-2011 due to insufficient recruitment of patients. No safety reasons contributed to the termination of the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
6 Years to 10 Years
Sex
All
01

Study summary

The planned study focuses on the effect of a one year Somatropin treatment (0.035 mg/kg/d or 0.067 mg/kg/d) in short children born SGA on neuromuscular function and cognitive performance.

02

Conditions studied

  • Growth Hormone Therapy
  • Infant, Small for Gestational Age
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-pubertal boys between 6 and 10 years of age or girls between 6 and 9 years of age.
  • Birth length- and/or birth weight-SDS adjusted to gestational age \< -2.0 (Voigt et al. 2002, Voigt et al. 2006 or Lawrence et al. 1989).
  • Current height-SDS \< -2.5 (Brandt/Reinken 1992) and parental adjusted height-SDS below -1 (Hermanussen and Cole 2003).
  • Growth velocity SDS \< 0 during the last year before inclusion (Brandt/Reinken 1988).

Exclusion criteria

Exclusion Criteria:

  • Severe SGA (birth weight or length \< -4 SD) and dysmorphic features.
  • Severe pre-maturity (GA \< 32 weeks of gestation).
  • Severe perinatal complications like asphyxia, sepsis, necrotizing enterocolitis (NEC), respiratory distress syndrome, if associated with long-term sequelae (like short bowel syndrome, bronchopulmonary dysplasia (BPD), cerebral palsy etc).
  • Inability to perform one- or two leg jumps from a standing position.
  • Prior GH treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Active comparator
    Treatment Group

    Somatropin for 12 months

    Drug: Somatropin

  • Other
    Control Group

    In the first 6 months no intervention, afterwards Somatropin for 12 months

    Drug: Somatropin

Interventions

  • Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.

  • Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6

    Peak jump power (PJP) was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline and Month 6

  2. Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6

    PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline and Month 6

  3. Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6

    PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline and Month 6

  4. Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6

    PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline and Month 6

  5. Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6

    Vmax was measured by Leonardo Jumping Platform during two-leg jump.

    Time frame: Baseline and Month 6

  6. Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Per Protocol (PP) Population at Month 6

    Vmax was measured by Leonardo Jumping Platform during two-leg jump.

    Time frame: Baseline and Month 6

Secondary outcomes

  1. Change From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Month 6

    K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces\&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme \[greater than (\>) 131\], above average (116-130), average (85-115), below average (70-84), lower extreme \[less than (\<) 69\].

    Time frame: Baseline and Month 6

  2. Change From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Months 12 and 18

    K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces\&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme \[greater than (\>) 131\], above average (116-130), average (85-115), below average (70-84), lower extreme \[less than (\<) 69\].

    Time frame: Baseline, Month 12 and Month 18

  3. Change From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Month 6

    The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results.

    Time frame: Baseline and Month 6

  4. Change From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Months 12 and 18

    The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results.

    Time frame: Baseline, Month 12 and Month 18

  5. Change From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Month 6

    NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores\[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)\].Scores were rated as below average(\<40), average(40-60), above average(\>60) and working time ranging between 9-12 minutes.

    Time frame: Baseline and Month 6

  6. Change From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Months 12 and 18

    NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores\[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)\].Scores were rated as below average(\<40), average(40-60), above average(\>60) and working time ranging between 9-12 minutes.

    Time frame: Baseline, Month 12 and Month 18

  7. Change From Baseline in Intellectual Performance of Children Using Child Behavior Checklist 4-18 Years (CBCL 4-18) at Months 6, 12 and 18

    CBCL was standardized for children ages 4 to 18 years and measured child internalizing and externalizing behaviors and total problems. The 4-18 years' checklist contains 140 questions and responses were recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The range of possible values was 0-280 (0=good to 280=worst).

    Time frame: Baseline, Month 6, Month 12 and Month 18

  8. Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; One-leg-jump) at Months 6, 12 and 18

    PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during one leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 6 , Month 12 and Month 18

  9. Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; One-leg-jump) at Months 6, 12 and 18

    PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during one leg jump. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 6, Month 12 and Month 18

  10. Change From Baseline in Maximum Jump Velocity (Vmax; One-leg-jump) at Months 6, 12 and 18

    Vmax was measured by Leonardo Jumping Platform during one leg jump.

    Time frame: Baseline, Month 6, Month 12 and Month 18

  11. Change From Baseline in Five-chair Rising Test- Peak Jump Power (PJP) at Month 6

    The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity).

    Time frame: Baseline and Month 6

  12. Change From Baseline in Five-chair Rising Test-Peak Jump Power (PJP) at Months 12 and 18

    The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity).

    Time frame: Baseline, Month 12 and Month 18

  13. Change From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Month 6

    The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.

    Time frame: Baseline and Month 6

  14. Change From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Months 12 and 18

    The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.

    Time frame: Baseline, Month 12 and Month 18

  15. Change From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Month 6

    The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity.

    Time frame: Baseline and Month 6

  16. Change From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Months 12 and 18

    The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity.

    Time frame: Baseline, Month 12 and Month 18

  17. Change From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Month 6

    Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests.

    Time frame: Baseline and Month 6

  18. Change From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Months 12 and 18

    Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests.

    Time frame: Baseline, Month 12 and Month 18

  19. Change From Baseline in One-chair Rising Test-Peak Jump Power (PJP) at Months 6, 12 and 18

    The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJP is defined as the peak of the calculated power (force multiplied by velocity).

    Time frame: Baseline, Month 6 , Month 12 and Month 18

  20. Change From Baseline in One-chair Rising Test-Peak Jump Force (PJF) at Months 6, 12 and 18

    The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.

    Time frame: Baseline, Month 6 , Month 12 and Month 18

  21. Change From Baseline in One-chair Rising Test (Time to Perform the Tasks) at Months 6, 12 and 18

    The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising).

    Time frame: Baseline, Month 6 , Month 12 and Month 18

  22. Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Month 6

    MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline and Month 6

  23. Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Months 12 and 18

    MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 12 and Month 18

  24. Mean Upper Arm Circumference

    Time frame: Baseline, Month 6, Month 12 and Month 18

  25. Mean Thigh Circumference

    Thigh measurements were taken as a mean of 3 consecutive measurements at upper thigh about an inch down from the crotch line.

    Time frame: Baseline, Month 6, Month 12 and Month 18

  26. Mean Calf Circumference

    Calf measurements were taken as a mean of 3 consecutive measurements at largest part of calf muscle, usually about 4 inches down from below the knee.

    Time frame: Baseline, Month 6, Month 12 and Month 18

  27. Mean Height at Month 6

    Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer.

    Time frame: Month 6

  28. Mean Height at Months 12 and 18

    Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer.

    Time frame: Month 12 and Month 18

  29. Mean Growth Velocity at Month 6

    Growth velocity measures the annual rate of increase in height.

    Time frame: Month 6

  30. Mean Growth Velocity at Months 12 and 18

    Growth velocity measures the annual rate of increase in height.

    Time frame: Month 12 and Month 18

  31. Mean Height-Standard Deviation Score (SDS) at Month 6

    Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.

    Time frame: Month 6

  32. Mean Height-Standard Deviation Score (SDS) at Months 12 and 18

    Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.

    Time frame: Month 12 and Month 18

  33. Mean Growth Velocity-Standard Deviation Score (SDS) at Month 6

    Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.

    Time frame: Month 6

  34. Mean Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18

    Time frame: Month 12 and Month 18

  35. Change From Baseline in Height-Standard Deviation Score (SDS) at Month 6

    Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline and Month 6

  36. Change From Baseline in Height-Standard Deviation Score (SDS) at Months 12 and 18

    Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 12 and Month 18

  37. Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Month 6

    Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.

    Time frame: Baseline and Month 6

  38. Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18

    Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.

    Time frame: Baseline, Month 12 and Month 18

  39. Sitting Height-Standard Deviation Score (SDS)

    Sitting height was measured using a stadiometer with a specialized chair. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 6, Month 12 and Month 18

  40. Body Mass Index-Standard Deviation Score (BMI-SDS)

    The BMI was used to measure body fat based on height and weight. It was calculated by body weight (kg) divided by the height (m) squared. The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 6, Month 12 and Month 18

  41. Change From Baseline in Head Circumference at Months 6, 12 and 18

    The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion).

    Time frame: Baseline, Month 6, Month 12 and Month 18

  42. Change From Baseline in Head Circumference-Standard Deviation Score (SDS) at Months 6, 12 and 18

    The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion). The SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 6, Month 12 and Month 18

  43. Change From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Month 6

    Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline and Month 6

  44. Change From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Months 12 and 18

    Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 12 and Month 18

Other outcomes

  1. Change From Baseline in Bone Density Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months

    Bone Mineral Density (BMD) was measured by pqCT. The Z-score measures the distance of the measured BMD value from the appropriate normal age matched population mean value in units of standard deviation of this population. More negative scores indicate less BMD compared to age matched population and more positive scores indicate higher BMD compared to age matched population.

    Time frame: Baseline, Month 6, Month 12 and Month 18

  2. Change From Baseline in Bone Structure Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months

    Bone structure was measured by pqCT.Parameters included:total area,cortical area,marrow area,cortical thickness,cortical density of the radius,bone strength,cross-sectional muscle and fat area,total bone density,bone mineral count,trabecular BMD,bone cross-sectional area.Baseline and post-baseline SDS values transformed to age and sex specific z-score(\[Ln(test result/M)\]/S);Ln=natural logarithm;M=age-/height- and sex-specific mean value;S=age-/height- and sex-specific coefficient of variation).Positive values are above the average for participant's age and sex;negative values are below.

    Time frame: Baseline, Month 6, Month 12 and Month 18

  3. Change From Baseline in Bone Stability Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months

    Bone stability was measured by pqCT. Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- (or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

    Time frame: Baseline, Month 6, Month 12 and Month 18

07

Results

Posted Feb 29, 2012
Limitations and caveats
The study was prematurely discontinued, therefore not all data was powered.

Participant flow

Participant flow — Overall Study
MilestoneSomatropinControl Arm
Started1211
Treated1210
Completed85
Not completed46
Withdrew: Withdrawal by subject10
Withdrew: Does not meet inclusion criteria10
Withdrew: Terminated by sponsor25
Withdrew: Randomized but not treated01

Outcome measures

PrimaryChange From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6

Peak jump power (PJP) was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · Watt/kilogram (W/kg)
Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6
Watt/kilogram (W/kg)SomatropinControl Arm
Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6-0.15 ± 1.010.28 ± 0.51
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.7232 (The statistical test was 2-sided and performed at the 5 percent significance level.) · Least squares (ls) mean difference: -0.43 · 95% CI -3.93 to 3.08
PrimaryChange From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6

PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · W/kg
Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6
W/kgSomatropinControl Arm
Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6-1.02 ± 0.430.59 ± 0.27
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.1941 (The statistical test was 2-sided and performed at the 5 percent significance level.) · Ls mean difference: -1.61 · 95% CI -8.04 to 4.82
PrimaryChange From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6

PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · Newtons
Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6
NewtonsSomatropinControl Arm
Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6-0.70 ± 0.62-0.55 ± 0.29
SecondaryChange From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Month 6

K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces\&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme \[greater than (\>) 131\], above average (116-130), average (85-115), below average (70-84), lower extreme \[less than (\<) 69\].

Time frame:
Baseline and Month 6
Reported as:
Mean · Units on a scale
Change From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Month 6
Units on a scaleSomatropinControl Arm
Baseline (Sequential Processing)25.7 ± 8.3528.5 ± 8.33
Change at Month 6 (Sequential Processing)2.6 ± 5.82-1.9 ± 4.15
Baseline (Simultaneous Processing)45.7 ± 7.2049.8 ± 12.74
Change at Month 6 (Simultaneous Processing)-0.1 ± 4.531.5 ± 4.30
Baseline (Achievement)300.7 ± 66.83341.8 ± 76.88
Change at Month 6 (Achievement)32.1 ± 48.7916.7 ± 27.52
Baseline (Nonverbal)46.2 ± 8.6549.8 ± 13.21
Change at Month 6 (Nonverbal)-1.4 ± 3.780.0 ± 5.35
Baseline (Mental Processing Composite)70.0 ± 12.3878.1 ± 19.95
Change at Month 6 (Mental Processing Composite)1.4 ± 6.39-0.9 ± 7.28
Statistical analysis
  • Somatropin vs Control Arm · Kruskal-Wallis · p = 0.0532 (The statistical test was 2-sided and performed at the 5 percent significance level.)
  • Somatropin vs Control Arm · Kruskal-Wallis · p = 0.3383 (The statistical test was 2-sided and performed at the 5 percent significance level.)
  • Somatropin vs Control Arm · Kruskal-Wallis · p = 0.6830 (The statistical test was 2-sided and performed at the 5 percent significance level.)
  • Somatropin vs Control Arm · Kruskal-Wallis · p = 0.4935 (The statistical test was 2-sided and performed at the 5 percent significance level.)
  • Somatropin vs Control Arm · Kruskal-Wallis · p = 0.3458 (The statistical test was 2-sided and performed at the 5 percent significance level.)
SecondaryChange From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Months 12 and 18

K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces\&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme \[greater than (\>) 131\], above average (116-130), average (85-115), below average (70-84), lower extreme \[less than (\<) 69\].

Time frame:
Baseline, Month 12 and Month 18
Reported as:
Mean · Units on a scale

No measurements were reported for this outcome.

SecondaryChange From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Month 6

The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results.

Time frame:
Baseline and Month 6
Reported as:
Mean · Seconds
Change From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Month 6
SecondsSomatropinControl Arm
Baseline (Distractibility)554.3 ± 201.08514.5 ± 127.41
Change at 6 Month (Distractibility) (n= 7, 10)5.6 ± 230.95-11.4 ± 139.52
Baseline (Alertness)433.9 ± 140.74384.6 ± 124.94
Change at 6 Month (Alertness) (n= 8, 10)-16.1 ± 80.854.0 ± 107.42
Baseline (Flexibility)1350.0 ± 470.501313.0 ± 477.19
Change at 6 Month (Flexibility) (n= 8, 10)-192.0 ± 492.73-211.0 ± 589.41
Baseline (Go/No Go)539.8 ± 106.73514.9 ± 91.95
Change at 6 Month (Go/No Go) (n= 8, 9)35.6 ± 113.38-50.2 ± 69.90
Baseline (Vigilance)822.2 ± 200.65693.4 ± 118.01
Change at 6 Month (Vigilance) (n= 7, 10)-146.0 ± 278.60-31.2 ± 107.62
Statistical analysis
  • Somatropin vs Control Arm · Kruskal-Wallis · p = 0.6256 (The statistical test was 2-sided and performed at the 5 percent significance level.)
  • Somatropin vs Control Arm · Kruskal-Wallis · p = 0.8590 (The statistical test was 2-sided and performed at the 5 percent significance level.)
  • Somatropin vs Control Arm · Kruskal-Wallis · p = 1.0000 (The statistical test was 2-sided and performed at the 5 percent significance level.)
  • Somatropin vs Control Arm · Kruskal-Wallis · p = 0.1234 (The statistical test was 2-sided and performed at the 5 percent significance level.)
  • Somatropin vs Control Arm · Kruskal-Wallis · p = 0.3291 (The statistical test was 2-sided and performed at the 5 percent significance level.)
SecondaryChange From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Months 12 and 18

The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results.

Time frame:
Baseline, Month 12 and Month 18
Reported as:
Mean · Seconds

No measurements were reported for this outcome.

SecondaryChange From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Month 6

NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores\[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)\].Scores were rated as below average(\<40), average(40-60), above average(\>60) and working time ranging between 9-12 minutes.

Time frame:
Baseline and Month 6
Reported as:
Mean · Units on a scale
Change From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Month 6
Units on a scaleSomatropinControl Arm
Baseline (Instability Index)0.3 ± 0.150.2 ± 0.21
Change at Month 6 (Instability Index)-0.1 ± 0.11-0.1 ± 0.20
Baseline (Working Time)227.0 ± 44.27218.3 ± 76.89
Change at Month 6 (Working Time)10.6 ± 92.95-11.1 ± 34.86
Baseline [T-scores (1)]39.9 ± 13.6043.9 ± 16.53
Change at Month 6 [T-scores (1)]4.4 ± 11.646.7 ± 12.12
Baseline [T-scores (2)]41.6 ± 12.9746.8 ± 14.40
Change at Month 6 [T-scores (2)]5.0 ± 10.72-0.6 ± 5.50
Baseline [T-scores (3)]45.9 ± 14.8948.1 ± 18.20
Change at Month 6 [T-scores (3)]1.5 ± 5.158.3 ± 12.24
Baseline [T-scores (4)]39.3 ± 16.9746.4 ± 16.03
Change at Month 6 [T-scores (4)]5.6 ± 15.531.4 ± 11.75
Baseline [T-scores (5)]43.3 ± 11.1243.6 ± 15.13
Change at Month 6 [T-scores (5)]2.6 ± 9.837.7 ± 12.59
Baseline [T-scores (6)]44.9 ± 15.8352.9 ± 19.96
Change at Month 6 [T-scores (6)]0.9 ± 16.55-7.4 ± 14.88
Baseline [Age-corrected T-scores (1)]33.4 ± 12.1838.6 ± 13.43
Change at Month 6 [Age-corrected T-scores (1)]6.0 ± 10.215.2 ± 11.26
Baseline [Age-corrected T-scores (2)]51.3 ± 7.5554.5 ± 8.10
Change at Month 6 [Age-corrected T-scores (2)]3.1 ± 5.59-0.1 ± 3.38
Baseline [Age-corrected T-scores (3)]40.0 ± 13.8641.1 ± 16.38
Change at Month 6 [Age-corrected T-scores (3)]0.6 ± 4.477.8 ± 12.13
Baseline [Age-corrected T-scores (4)]37.4 ± 17.0145.0 ± 15.21
Change at Month 6 [Age-corrected T-scores (4)]6.3 ± 14.574.1 ± 10.63
Baseline [Age-corrected T-scores (5)]35.0 ± 11.8837.3 ± 13.48
Change at Month 6 [Age-corrected T-scores (5)]3.3 ± 10.736.9 ± 12.57
Baseline [Age-corrected T-scores (6)]50.0 ± 16.4955.5 ± 16.64
Change at Month 6 [Age-corrected T-scores (6)]1.5 ± 19.06-4.1 ± 13.77
SecondaryChange From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Months 12 and 18

NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores\[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)\].Scores were rated as below average(\<40), average(40-60), above average(\>60) and working time ranging between 9-12 minutes.

Time frame:
Baseline, Month 12 and Month 18
Reported as:
Mean · Units on a scale

No measurements were reported for this outcome.

SecondaryChange From Baseline in Intellectual Performance of Children Using Child Behavior Checklist 4-18 Years (CBCL 4-18) at Months 6, 12 and 18

CBCL was standardized for children ages 4 to 18 years and measured child internalizing and externalizing behaviors and total problems. The 4-18 years' checklist contains 140 questions and responses were recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The range of possible values was 0-280 (0=good to 280=worst).

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Mean · Units on a scale

No measurements were reported for this outcome.

SecondaryChange From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; One-leg-jump) at Months 6, 12 and 18

PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during one leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 6 , Month 12 and Month 18
Reported as:
Mean · W/kg

No measurements were reported for this outcome.

SecondaryChange From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; One-leg-jump) at Months 6, 12 and 18

PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during one leg jump. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Mean · Newtons

No measurements were reported for this outcome.

SecondaryChange From Baseline in Maximum Jump Velocity (Vmax; One-leg-jump) at Months 6, 12 and 18

Vmax was measured by Leonardo Jumping Platform during one leg jump.

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Mean · m/s

No measurements were reported for this outcome.

SecondaryChange From Baseline in Five-chair Rising Test- Peak Jump Power (PJP) at Month 6

The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity).

Time frame:
Baseline and Month 6
Reported as:
Mean · kilowatt (kW)
Change From Baseline in Five-chair Rising Test- Peak Jump Power (PJP) at Month 6
kilowatt (kW)SomatropinControl Arm
Baseline0.1 ± 0.070.1 ± 0.05
Change at Month 60.0 ± 0.070.0 ± 0.05
SecondaryChange From Baseline in Five-chair Rising Test-Peak Jump Power (PJP) at Months 12 and 18

The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity).

Time frame:
Baseline, Month 12 and Month 18
Reported as:
Mean · kW

No measurements were reported for this outcome.

SecondaryChange From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Month 6

The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.

Time frame:
Baseline and Month 6
Reported as:
Mean · kilonewton (kN)
Change From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Month 6
kilonewton (kN)SomatropinControl Arm
Baseline0.4 ± 0.110.4 ± 0.19
Change at Month 6-0.0 ± 0.230.0 ± 0.20
SecondaryChange From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Months 12 and 18

The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.

Time frame:
Baseline, Month 12 and Month 18
Reported as:
Mean · kN

No measurements were reported for this outcome.

SecondaryChange From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Month 6

The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity.

Time frame:
Baseline and Month 6
Reported as:
Mean · m/s
Change From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Month 6
m/sSomatropinControl Arm
Baseline0.7 ± 0.220.6 ± 0.16
Change at Month 60.2 ± 0.290.0 ± 0.18
SecondaryChange From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Months 12 and 18

The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity.

Time frame:
Baseline, Month 12 and Month 18
Reported as:
Mean · m/s

No measurements were reported for this outcome.

SecondaryChange From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Month 6

Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests.

Time frame:
Baseline and Month 6
Reported as:
Mean · seconds
Change From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Month 6
secondsSomatropinControl Arm
Baseline (Average rise time)1.2 ± 0.900.7 ± 0.31
Change at Month 6 (Average rise time)-0.5 ± 1.150.1 ± 0.27
Baseline (Average time per test)2.0 ± 0.702.3 ± 0.60
Change at Month 6 (Average time per test)-0.2 ± 0.54-0.1 ± 0.87
Baseline (Total time to perform 5 tests)9.6 ± 3.9110.8 ± 2.24
Change at Month 6 (Total time to perform 5 tests)0.1 ± 3.042.0 ± 8.48
SecondaryChange From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Months 12 and 18

Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests.

Time frame:
Baseline, Month 12 and Month 18
Reported as:
Mean · seconds

No measurements were reported for this outcome.

SecondaryChange From Baseline in One-chair Rising Test-Peak Jump Power (PJP) at Months 6, 12 and 18

The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJP is defined as the peak of the calculated power (force multiplied by velocity).

Time frame:
Baseline, Month 6 , Month 12 and Month 18
Reported as:
Mean · kW

No measurements were reported for this outcome.

SecondaryChange From Baseline in One-chair Rising Test-Peak Jump Force (PJF) at Months 6, 12 and 18

The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.

Time frame:
Baseline, Month 6 , Month 12 and Month 18
Reported as:
Mean · kN

No measurements were reported for this outcome.

SecondaryChange From Baseline in One-chair Rising Test (Time to Perform the Tasks) at Months 6, 12 and 18

The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising).

Time frame:
Baseline, Month 6 , Month 12 and Month 18
Reported as:
Mean · seconds

No measurements were reported for this outcome.

SecondaryChange From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Month 6

MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · kg
Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Month 6
kgSomatropinControl Arm
Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Month 61.28 ± 1.691.13 ± 1.64
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.9560 (The statistical test was 2-sided and performed at the 5 percent significance level.) · Ls mean difference: 0.14 · 95% CI -5.71 to 6.00
SecondaryChange From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Months 12 and 18

MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 12 and Month 18
Reported as:
Least squares mean · kg

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline in Bone Density Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months

Bone Mineral Density (BMD) was measured by pqCT. The Z-score measures the distance of the measured BMD value from the appropriate normal age matched population mean value in units of standard deviation of this population. More negative scores indicate less BMD compared to age matched population and more positive scores indicate higher BMD compared to age matched population.

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Least squares mean · z-score

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline in Bone Structure Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months

Bone structure was measured by pqCT.Parameters included:total area,cortical area,marrow area,cortical thickness,cortical density of the radius,bone strength,cross-sectional muscle and fat area,total bone density,bone mineral count,trabecular BMD,bone cross-sectional area.Baseline and post-baseline SDS values transformed to age and sex specific z-score(\[Ln(test result/M)\]/S);Ln=natural logarithm;M=age-/height- and sex-specific mean value;S=age-/height- and sex-specific coefficient of variation).Positive values are above the average for participant's age and sex;negative values are below.

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Least squares mean · z-score

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline in Bone Stability Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months

Bone stability was measured by pqCT. Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- (or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Least squares mean · z-score

No measurements were reported for this outcome.

SecondaryMean Upper Arm Circumference
Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Mean · centimeter (cm)

No measurements were reported for this outcome.

SecondaryMean Thigh Circumference

Thigh measurements were taken as a mean of 3 consecutive measurements at upper thigh about an inch down from the crotch line.

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Mean · cm

No measurements were reported for this outcome.

SecondaryMean Calf Circumference

Calf measurements were taken as a mean of 3 consecutive measurements at largest part of calf muscle, usually about 4 inches down from below the knee.

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Mean · cm

No measurements were reported for this outcome.

SecondaryMean Height at Month 6

Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer.

Time frame:
Month 6
Reported as:
Mean · cm
Mean Height at Month 6
cmSomatropinControl Arm
Mean Height at Month 6112.8 ± 5.13115.0 ± 7.93
SecondaryMean Height at Months 12 and 18

Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer.

Time frame:
Month 12 and Month 18
Reported as:
Mean · cm

No measurements were reported for this outcome.

SecondaryMean Growth Velocity at Month 6

Growth velocity measures the annual rate of increase in height.

Time frame:
Month 6
Reported as:
Mean · cm/year
Mean Growth Velocity at Month 6
cm/yearSomatropinControl Arm
Mean Growth Velocity at Month 68.2 ± 1.934.6 ± 1.44
SecondaryMean Growth Velocity at Months 12 and 18

Growth velocity measures the annual rate of increase in height.

Time frame:
Month 12 and Month 18
Reported as:
Mean · cm/year

No measurements were reported for this outcome.

SecondaryMean Height-Standard Deviation Score (SDS) at Month 6

Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.

Time frame:
Month 6
Reported as:
Mean · cm
Mean Height-Standard Deviation Score (SDS) at Month 6
cmSomatropinControl Arm
Mean Height-Standard Deviation Score (SDS) at Month 6-3.1 ± 0.86-3.7 ± 0.77
SecondaryMean Height-Standard Deviation Score (SDS) at Months 12 and 18

Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.

Time frame:
Month 12 and Month 18
Reported as:
Mean · cm

No measurements were reported for this outcome.

SecondaryMean Growth Velocity-Standard Deviation Score (SDS) at Month 6

Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.

Time frame:
Month 6
Reported as:
Mean · cm/year
Mean Growth Velocity-Standard Deviation Score (SDS) at Month 6
cm/yearSomatropinControl Arm
Mean Growth Velocity-Standard Deviation Score (SDS) at Month 63.4 ± 2.62-1.1 ± 1.43
SecondaryMean Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18
Time frame:
Month 12 and Month 18
Reported as:
Mean · cm/year

No measurements were reported for this outcome.

SecondaryChange From Baseline in Height-Standard Deviation Score (SDS) at Month 6

Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · cm
Change From Baseline in Height-Standard Deviation Score (SDS) at Month 6
cmSomatropinControl Arm
Change From Baseline in Height-Standard Deviation Score (SDS) at Month 60.33 ± 0.21-0.22 ± 0.25
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.1107 (The statistical test was 2-sided and performed at the 5 percent significance level.) · Ls mean difference: 0.55 · 95% CI -0.15 to 1.25
SecondaryChange From Baseline in Height-Standard Deviation Score (SDS) at Months 12 and 18

Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 12 and Month 18
Reported as:
Least squares mean · cm

No measurements were reported for this outcome.

SecondaryChange From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Month 6

Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · cm/year
Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Month 6
cm/yearSomatropinControl Arm
Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Month 63.89 ± 1.02-0.77 ± 1.40
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.0161 (The statistical test was 2-sided and performed at the 5 percent significance level.) · Ls mean difference: 4.67 · 95% CI 1.13 to 8.21
SecondaryChange From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18

Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.

Time frame:
Baseline, Month 12 and Month 18
Reported as:
Least squares mean · cm/year

No measurements were reported for this outcome.

PrimaryChange From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6

PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · Newtons
Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6
NewtonsSomatropinControl Arm
Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6-0.83 ± 1.27-0.85 ± 0.73
PrimaryChange From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6

Vmax was measured by Leonardo Jumping Platform during two-leg jump.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · Meter/second (m/s)
Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6
Meter/second (m/s)SomatropinControl Arm
Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 60.01 ± 0.080.12 ± 0.09
PrimaryChange From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Per Protocol (PP) Population at Month 6

Vmax was measured by Leonardo Jumping Platform during two-leg jump.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · m/s
Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Per Protocol (PP) Population at Month 6
m/sSomatropinControl Arm
Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Per Protocol (PP) Population at Month 60.01 ± 0.050.25 ± 0.06
SecondarySitting Height-Standard Deviation Score (SDS)

Sitting height was measured using a stadiometer with a specialized chair. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Mean · cm

No measurements were reported for this outcome.

SecondaryBody Mass Index-Standard Deviation Score (BMI-SDS)

The BMI was used to measure body fat based on height and weight. It was calculated by body weight (kg) divided by the height (m) squared. The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Mean · Kilogram per square meter (kg/m^2)

No measurements were reported for this outcome.

SecondaryChange From Baseline in Head Circumference at Months 6, 12 and 18

The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion).

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Mean · cm

No measurements were reported for this outcome.

SecondaryChange From Baseline in Head Circumference-Standard Deviation Score (SDS) at Months 6, 12 and 18

The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion). The SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 6, Month 12 and Month 18
Reported as:
Mean · cm

No measurements were reported for this outcome.

SecondaryChange From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Month 6

Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · Millimeter (mm)
Change From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Month 6
Millimeter (mm)SomatropinControl Arm
Change at Month 6 (Triceps SDS)-0.41 ± 0.16-0.06 ± 0.18
Change at Month 6 (Subscapular SDS)-0.30 ± 0.10-0.16 ± 0.13
Change at Month 6 (Suprailiac SDS)-0.60 ± 0.07-0.33 ± 0.12
Statistical analysis
  • Somatropin vs Control Arm · ANCOVA · p = 0.1870 (The statistical test was 2-sided and performed at the 5 percent significance level.) · Ls mean difference: -0.35 · 95% CI -0.89 to 0.20
  • Somatropin vs Control Arm · ANCOVA · p = 0.3494 (The statistical test was 2-sided and performed at the 5 percent significance level.) · Ls mean difference: -0.15 · 95% CI -0.49 to 0.19
  • Somatropin vs Control Arm · ANCOVA · p = 0.0458 (The statistical test was 2-sided and performed at the 5 percent significance level.) · Ls mean difference: -0.27 · 95% CI -0.54 to -0.01
SecondaryChange From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Months 12 and 18

Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 12 and Month 18
Reported as:
Least squares mean · mm

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Somatropin—0/12 (0%)10/12 (83.3%)
Control Arm—0/11 (0%)7/11 (63.6%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventSomatropinControl Arm
HeadacheNervous system disorders2/122/11
Respiratory tract infectionInfections and infestations2/120/11
ConjunctivitisEye disorders0/121/11
ConstipationGastrointestinal disorders0/121/11
Acute tonsillitisInfections and infestations0/121/11
BronchitisInfections and infestations0/121/11
GastroenteritisInfections and infestations0/121/11
Otitis mediaInfections and infestations1/121/11
RhinitisInfections and infestations0/121/11
TonsillitisInfections and infestations0/121/11

Baseline characteristics

Age Continuous
Age Continuous(Years)SomatropinControl ArmTotal
Mean6.6 ± 1.07.6 ± 1.47.1 ± 1.3
Sex: Female, Male
Sex: Female, Male(Participants)SomatropinControl ArmTotal
Female3811
Male9312
08

Study locations

10 sites
  • Pfizer Investigational Site
    Berlin, 13353, Germany
  • Pfizer Investigational Site
    Bonn, 53113, Germany
  • Pfizer Investigational Site
    Datteln, 45711, Germany
  • Pfizer Investigational Site
    Dresden, 01307, Germany
  • Pfizer Investigational Site
    Erlangen, 91054, Germany
  • Pfizer Investigational Site
    Essen, 45122, Germany
  • Pfizer Investigational Site
    Heidelberg, 69120, Germany
  • Pfizer Investigational Site
    Kiel, 24105, Germany
  • Pfizer Investigational Site
    Koeln, 50937, Germany
  • Pfizer Investigational Site
    Muenchen, 80337, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2008
First posted
Feb 28, 2008
Start
Jul 2008
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Feb 29, 2012
Last update
Feb 29, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00625872
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 28, 2008
Start date
Jul 2008
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Feb 29, 2012
Last update
Feb 29, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion